Literature DB >> 25680376

Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.

Tom Donnem1, Sigurd M Hald2, Erna-Elise Paulsen3, Elin Richardsen4, Samer Al-Saad4, Thomas K Kilvaer5, Odd Terje Brustugun6, Aslaug Helland6, Marius Lund-Iversen7, Mette Poehl8, Karen Ege Olsen9, Henrik J Ditzel10, Olfred Hansen11, Khalid Al-Shibli12, Yury Kiselev13, Torkjel M Sandanger14, Sigve Andersen5, Francesco Pezzella15, Roy M Bremnes3, Lill-Tove Busund4.   

Abstract

PURPOSE: Immunoscore is a prognostic tool defined to quantify in situ immune cell infiltrates, which appears to be superior to the tumor-node-metastasis (TNM) classification in colorectal cancer. In non-small cell lung cancer (NSCLC), no immunoscore has been established, but in situ tumor immunology is recognized as highly important. We have previously evaluated the prognostic impact of several immunological markers in NSCLC, yielding the density of stromal CD8(+) tumor-infiltrating lymphocytes (TIL) as the most promising candidate. Hence, we validate the impact of stromal CD8(+) TIL density as an immunoscore in NSCLC. EXPERIMENTAL
DESIGN: The prognostic impact of stromal CD8(+) TILs was evaluated in four different cohorts from Norway and Denmark consisting of 797 stage I-IIIA NSCLC patients. The Tromso cohort (n = 155) was used as training set, and the results were further validated in the cohorts from Bodo (n = 169), Oslo (n = 295), and Denmark (n = 178). Tissue microarrays and clinical routine CD8 staining were used for all cohorts.
RESULTS: Stromal CD8(+) TIL density was an independent prognostic factor in the total material (n = 797) regardless of the endpoint: disease-free survival (P < 0.001), disease-specific survival (P < 0.001), or overall survival (P < 0.001). Subgroup analyses revealed significant prognostic impact of stromal CD8(+) TIL density within each pathologic stage (pStage). In multivariate analysis, stromal CD8(+) TIL density and pStage were independent prognostic variables.
CONCLUSIONS: Stromal CD8(+) TIL density has independent prognostic impact in resected NSCLC, adds prognostic impact within each pStage, and is a good candidate marker for establishing a TNM-Immunoscore. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25680376     DOI: 10.1158/1078-0432.CCR-14-1905

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  124 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?

Authors:  Matthew Evans; Brendan O'Sullivan; Matthew Smith; Philippe Taniere
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 3.  Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.

Authors:  Lizza E Hendriks; Etienne Rouleau; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2018-12

4.  Immunotherapy response modeling by ex-vivo organ culture for lung cancer.

Authors:  Iris Kamer; Elizabeta Bab-Dinitz; Oranit Zadok; Efrat Ofek; Teodor Gottfried; Inbal Daniel-Meshulam; Goni Hout-Siloni; Alon Ben Nun; Iris Barshack; Amir Onn; Jair Bar
Journal:  Cancer Immunol Immunother       Date:  2021-01-23       Impact factor: 6.968

5.  Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.

Authors:  Marta Usó; Eloísa Jantus-Lewintre; Silvia Calabuig-Fariñas; Ana Blasco; Eva García Del Olmo; Ricardo Guijarro; Miguel Martorell; Carlos Camps; Rafael Sirera
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 6.  Biomarker for personalized immunotherapy.

Authors:  Si-Yang Liu; Yi-Long Wu
Journal:  Transl Lung Cancer Res       Date:  2019-11

7.  EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.

Authors:  Shaorong Yu; Huanhuan Sha; Xiaobing Qin; Yan Chen; Xiaoyou Li; Meiqi Shi; Jifeng Feng
Journal:  Oncogene       Date:  2020-01-30       Impact factor: 9.867

8.  Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.

Authors:  Seyer Safi; Yoshikane Yamauchi; Anchana Rathinasamy; Slava Stamova; Martin Eichhorn; Arne Warth; Geraldine Rauch; Hendrik Dienemann; Hans Hoffmann; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2017-09-08       Impact factor: 8.110

Review 9.  Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.

Authors:  Kazuhiko Shien; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba
Journal:  Lung Cancer       Date:  2016-06-21       Impact factor: 5.705

10.  PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.

Authors:  Marius Ilie; Alexander T Falk; Catherine Butori; Emmanuel Chamorey; Christelle Bonnetaud; Elodie Long; Sandra Lassalle; Katia Zahaf; Nicolas Vénissac; Jérôme Mouroux; Charlotte Cohen; Elisabeth Brambilla; Charles Hugo Marquette; Véronique Hofman; Paul Hofman
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.